Expertise in
22
conditions

Dr. John M. Mccarty

Oncology
Virginia Commonwealth University Health System Authority
1300 E Marshall St, 
Richmond, VA 
Accepting New Patients
Offers Telehealth
37 Years of Experience
Expertise in
22
conditions
Virginia Commonwealth University Health System Authority
1300 E Marshall St, 
Richmond, VA 

Overview

John Mccarty is an Oncologist practicing medicine in Richmond, Virginia. He has been practicing medicine for over 37 years.

Dr. Mccarty is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Colonoscopy, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 43 peer reviewed articles and participating in 8 clinical trials. Dr. Mccarty is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in VA

Hospital Affiliations

Medical College Of Virginia Hospitals
Vcu Health Tappahannock Hospital

Languages Spoken

English
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
HealthKeepers
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Piedmont
  • HMO
  • POS
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Virginia Commonwealth University Health System Authority
1300 E Marshall St, Richmond, VA 23298

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Drug, Other, Procedure
Study Drugs: Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Melphalan
Study Phase: Phase 3
An Open-Label, Phase 1/2 Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
An Open-Label, Phase 1/2 Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
Enrollment Status: Active_not_recruiting
Publish Date: July 06, 2026
Intervention Type: Biological
Study Drugs: Lisocabtagene Maraleucel, Ibrutinib
Study Phase: Phase 1/Phase 2
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Enrollment Status: Completed
Publish Date: January 05, 2026
Intervention Type: Other
Study Phase: Not Applicable
S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Lenalidomide, Daratumumab/rHuPH20
Study Phase: Phase 3
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: August 06, 2025
Intervention Type: Drug, Radiation, Procedure
Study Phase: Phase 2
A Phase 1, Non-Randomized, Open-Label/Phase 2, Randomized, Blinded Study of ProTmune™ (ex Vivo Programmed Mobilized Peripheral Blood Cells) Versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects With Hematologic Malignancies
A Phase 1, Non-Randomized, Open-Label/Phase 2, Randomized, Blinded Study of ProTmune™ (ex Vivo Programmed Mobilized Peripheral Blood Cells) Versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: February 08, 2023
Intervention Type: Biological
Study Drug: ProTmune Ex Vivo Programmed Mobilized Peripheral Cells
Study Phase: Phase 1/Phase 2
Adoptive Immunotherapy in Patients With Relapsed Hematological Malignancy: Effect of Duration and Intensity of Early GVHD Prophylaxis on Long-Term Clinical Outcomes
Adoptive Immunotherapy in Patients With Relapsed Hematological Malignancy: Effect of Duration and Intensity of Early GVHD Prophylaxis on Long-Term Clinical Outcomes
Enrollment Status: Completed
Publish Date: January 23, 2023
Intervention Type: Biological, Drug
Study Drugs: Mycophenolate Mofetil, Sargramostim, Filgrastim
Study Phase: Phase 2
A Phase II, Randomized Trial of Standard of Care, With or Without Midostaruin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With FLT3-ITD Mutated Acute Myeloid Leukemia
A Phase II, Randomized Trial of Standard of Care, With or Without Midostaruin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With FLT3-ITD Mutated Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: March 17, 2021
Intervention Type: Drug, Other
Study Phase: Phase 2
View 7 Less Clinical Trials

43 Total Publications

Are all mismatched donors the same in allogeneic hematopoietic cell transplantation for secondary acute myeloid leukemia in the posttransplant cyclophosphamide era?
Are all mismatched donors the same in allogeneic hematopoietic cell transplantation for secondary acute myeloid leukemia in the posttransplant cyclophosphamide era?
Journal: Bone marrow transplantation
Published: June 18, 2026
Similar Doctors
Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required

VCU Health System Stony Point

9000 Stony Point Pkwy, 
Richmond, VA 
 (7.6 miles away)
804-327-3055
Languages Spoken:
English, Portuguese, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Renato Martins is an Oncologist practicing medicine in Richmond, Virginia. Dr. Martins is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Salivary Gland Tumors, and Small Cell Lung Cancer (SCLC). Dr. Martins is currently accepting new patients.

Expertise in
30
conditions
Dr. Sosipatros A. Boikos
Hematology | Oncology
Expertise in
30
conditions
Dr. Sosipatros A. Boikos
Hematology | Oncology
Referral may be required

Virginia Commonwealth University Health System Authority

1250 E Marshall St, 
Richmond, VA 
 (0.1 miles away)
804-828-7999
Languages Spoken:
English, Greek
See accepted insurances
Accepting New Patients

Sosipatros Boikos is a Hematologist and an Oncologist practicing medicine in Richmond, Virginia. Dr. Boikos is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Synovial Sarcoma, Gastrointestinal Stromal Tumor, Adult Soft Tissue Sarcoma, Neuroendocrine Tumor, and Bone Marrow Aspiration. Dr. Boikos is currently accepting new patients.

Expertise in
17
conditions
Expertise in
17
conditions
Referral may be required

Women's Cancer & Wellness Institute

1401 Johnston Willis Drive, Suite 1100, 
North Chesterfield, VA 
 (7.6 miles away)
804-323-5040
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Randal West is an Oncologist practicing medicine in North Chesterfield, Virginia. Dr. West is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Sertoli-Leydig Cell Tumor, Ovarian Carcinosarcoma, Salpingo-Oophorectomy, and Gastrostomy. Dr. West is board certified in (Obstetrics & Gynecology, Gynecology), American Board Of Obstetrics & Gynecology, and (Obstetrics & Gynecology). Dr. West is currently accepting new patients.

Frequently Asked Questions about Dr. John M. Mccarty

How do I make an appointment with Dr. John M. Mccarty?

You can book an appointment with Dr. John M. Mccarty by calling their office at 804-828-4360. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. John M. Mccarty a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. John M. Mccarty is classified as an Distinguished expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. John M. Mccarty specialize in?

While Dr. John M. Mccarty is a Oncology, they have specific expertise in Multiple Myeloma, Acute Myeloid Leukemia (AML), and Acute Myeloblastic Leukemia without Maturation. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. John M. Mccarty participate in research or clinical trials?

Yes. Dr. John M. Mccarty has published 43 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. John M. Mccarty's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. John M. Mccarty accept my insurance?

Dr. John M. Mccarty accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 804-828-4360 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mccarty's expertise for a condition
ConditionClose
    View All 9 Distinguished Conditions
    View All 13 Advanced Conditions
    View All 17 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile